Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avecho Biotechnology Ltd V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Bullboard Posts
Post by 93Darkhorse93on Apr 08, 2017 1:35pm
195 Views
Post# 26096068

Pricing/Gross Margin will Improve with Demand Recovery...

Pricing/Gross Margin will Improve with Demand Recovery...I accept your skepticism but I must disagree, revenue growth will be accompanied by pricing power which should be pulled through to gross margin expansion.  Gross Margin is highly correlated to Rig Count growth which bottomed near the end of Q1 to the beginning of Q2 in 2016
 
In Q1 ’15 thy had revenue of 36.6M and gross margin of 11.16% (which includes amortization). That 25-30M range is a critical point for Aveda because that this the point at which Aveda’s cost structure begins to generate positive EBITDA.  Seeing that they already announced revenue for Q4 of 31M gross margin will continue to recover QoQ and YoY.
 
Since the Rig count is up another 28% from the beginning of the new year, you could be looking at 14M run rate monthly revenue or 168M for 2017 (Even if a single rig is not added from this level) when analyst are only at 140M.
 
Trading at only 3x 2017 EBITDA on my numbers its worth a look given your downside is limited as the financing was done right at this price.    

Bullboard Posts